DETROIT, May 10, 2013 (GLOBE NEWSWIRE) -- Nano Labs Corp. (OTCQB:CTLE) is pleased to announce today it has developed an innovative hemostatic material which it has filed for provisional patent and is currently presenting to the biomedical industry.
The new innovation includes a nano biotechnology hemostatic mesh, which creates a mechanical barrier stopping blood flow in wounds and integrates both physical and chemical protection, and antibacterial properties.
The proprietary nano material is made with polyvinyl nanofibers, graphene oxide sheets and plate nanoparticles which combine to produce a water-soluble synthetic polymer which has excellent film forming quality, a high tensile strength and flexibility, and allows for emulsifying of additional biomedical enhancing materials that would otherwise not be able to be blended together.
The result is a surgical mesh that allows blood platelets to adhere to the surface and offers physical and chemical protection to stimulate coagulation, and possess sustained release of antibacterial properties. The material is biocompatible, durable, and flexible enough to fit complex wounds, is stable and functional at extreme temperatures, has a long shelf life, and possesses antibacterial properties.
"There have been a number of patented hemostatic materials that are based on the use of nanofibers. However, these patents do not include the use of graphene oxide and silver nanoparticles, which gives our new product antibacterial properties and mechanical reinforcement," states Dr. Castano, Chief Innovations Officer of Nano Labs.
Silver's antimicrobial properties have been known for centuries and the bactericidal properties of silver nanoparticles are widely documented. Silver nanoparticles cause lysis of bacteria and do not pose a risk to the health of people. Graphene, which consists of carbon sheets (the thickness of a single atom), are used as a template for the assembly of the silver nanoparticles, enhancing the binding capacity of the nanoparticles and increasing its antimicrobial activity.
"The use of nanotechnology in medicine offers many exciting possibilities from disease targeting and drug delivery, to physical therapy and cell regeneration applications. From the point of view of nanotech we are at the perfect scale to manufacture, interface and heal at the molecular and cellular level. The size of nanomaterials is similar to that of most biological molecules and structures, for example a cell wall," states Dr. Castano. "In the case of our new surgical mesh, we have added nanomaterials and interfaced them with biological structures. We are very hopeful that our new product will assist in both hospital theatres worldwide decreasing post-op complications and in the field. Current practices for staunching bleeding wounds in the field are generally based on compression but this can be difficult to control or even achieve in the field. Our new product is designed to offer an inexpensive and practical alternative. Nanotechnology holds great promise in the field of medicine. Of all the benefits nanotechnology holds, the greatest promise to mankind I believe will be in medicine."
The Company is in early stage development and will update the public with a timeline for preclinical testing phases and future commercialization.
Note: This is the Company's second announcement in nano medical applications following the Company's press release of March 4, 2013 "Nano Labs Develops Diagnostic Technology to Identify Tuberculosis (TB) Through Novel Nanotechnologies. Researchers Present Industry With Promising Diagnostic Test Results Identifying TB Through Nano Biosensors."
About Nano Labs
Nano Labs Corp. (CTLE) is a nanotechnology research and development company which began during October 2012, but is able to access resources that encompass nearly 30 years of research and development in nanotechnology as well as hundreds of peer-reviewed and published research papers and other scholarly material. The Company's research and development team of scientists, designers, and engineers is focused on creating a portfolio of advanced products that could provide benefits to a variety of industries including: (i) consumer products, (ii) energy, (iii) materials, and (iv) healthcare. Through the use and integration of proprietary nano compounds, our goal is to evolve common products into new, revolutionary products in order to make the world a better place. Nano Labs shares are traded on the OTC Bulletin Board in the United States under the ticker CTLE. For more information, please visit www.NanoLabs.us.
The Nano Labs Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16293
Forward looking statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those laws. These forward-looking statements are based upon a number of assumptions and estimates that are subject to significant uncertainties that involve known and unknown risks, many of which are beyond our control and are not guarantees of future performance. Actual outcomes and results could materially differ from what is expressed, implied, or forecasted in any such forward-looking statements and any such difference may be caused by risk factors listed from time to time in the Company's news releases and/or its filings with the OTC Bulletin Board or as a result of other factors.
CONTACT: Contact Nano Labs Corp. Bernardo Camacho Chavarria President 1 (888) 806-2315
Source:Nano Labs Corp.